X4 Pharmaceuticals Inc. reported its third quarter 2025 financial results and provided a corporate update. The company announced a strategic shift, prioritizing the advancement of the 4WARD Phase 3 pivotal trial of mavorixafor in patients with moderate and severe chronic neutropenia. As part of its restructuring efforts since August, X4 implemented a 50% workforce reduction, resulting in approximately $13 million in annualized cost savings. The company has also increased the enrollment target for the 4WARD study to 176 patients, with enrollment now expected to be completed in the third quarter of 2026. X4 deprioritized the commercialization of mavorixafor (XOLREMDI) for WHIM syndrome, while maintaining patient access. The company completed two financial transactions totaling $240.3 million in gross proceeds, extending its cash runway to the end of 2028. X4 expects this financial position to support the completion of the 4WARD trial, a potential sNDA filing for the chronic neutropenia indication, and the possible launch of mavorixafor for this new indication by the end of 2028. Leadership changes included the promotion of John Volpone to Chief Operating Officer and expanded responsibilities for Dr. Adam Craig, now overseeing clinical development activities.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. X4 Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9568968-en) on November 05, 2025, and is solely responsible for the information contained therein.
Comments